Yue Cui

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 840 citations · Full text

Hematological Malignancy, Medicine, Malignant Blood Disorder +11

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 808 citations · Full text

Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain

Yukun Cao, Wenjuan Zeng, Yue Cui et al. · Cardiovascular Diabetology · 2018 · 90 citations · Full text

Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study

Yumin Li, Xiaoyu Han, Osamah Alwalid et al. · Diabetes Research and Clinical Practice · 2020 · 57 citations · Full text

Diabetes Management, Diabetes Epidemiology, Disease Risk Assessment +12

Association between myocardial extracellular volume and strain analysis through cardiovascular magnetic resonance with histological myocardial fibrosis in patients awaiting heart transplantation

Yue Cui, Yukun Cao, Jing Song et al. · Journal of Cardiovascular Magnetic Resonance · 2018 · 38 citations · Full text